Point-of-Care Rapid RNA test for HIV
HIV 护理点快速 RNA 检测
基本信息
- 批准号:9198875
- 负责人:
- 金额:$ 28.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-01 至 2018-06-30
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAntibodiesAppearanceBase SequenceBedside TestingsBiological AssayBloodBlood TestsBlood specimenCellular PhoneColorConsultDetectionDevelopmentDevicesDiagnosisDiagnosticEmergency SituationEquus caballusEyeFDA approvedGenesGoldHIVHIV-1HumanHuman immunodeficiency virus testImmobilizationImmunologic Deficiency SyndromesInfantJointsLateralLifeMedicalMolecularMothersNucleic AcidsNucleic acid sequencingPaperPerformancePeroxidasesPhasePublic HealthRNARNA purificationRadishReactionReportingResearchSamplingSignal TransductionSilverSpecificitySystemTechnologyTestingTranscriptUNICEFVirionVirus DiseasesWhole BloodWomanWorkabstractingamplification detectionassay developmentbasechemical transfer reactiondesignimaging softwareimprovedinnovationnanoparticlepoint of careviral RNAviral detection
项目摘要
Point-of-Care Rapid RNA test for HIV
CrossLife Technologies Inc.
Project Summary/Abstract
Current antibody point-of-care tests cannot distinguish between a mother's and baby's
antibodies to detect if an infant has become infected with Human Immunodeficiency
Virus (HIV). According to a recent joint WHO/UNAIDS/UNICEF report only an estimated
28 percent of babies born to HIV-positive mothers obtained an HIV test within the first
two months [1]. Therefore, there are unmet needs for new and improved diagnostics that
can be applied at the point-of-care to detect HIV infections. A highly sensitive, simple
paper strip molecular test that detects HIV at the point-of-care will be developed. The
target sequences are amplified using the TARA (Template-Assisted Rapid Assay)
technology which is composed of a template-dependent chemical transfer reaction with
high turnover, gold nanoparticle-HRP and lateral flow readout. The test should be rapid
(<30 minutes), and results in the appearance of colored bands that are detectable by
eye or are captured using a smartphone scanner.
艾滋病毒的即时快速RNA检测
CrossLife Technologies Inc.
项目总结/摘要
目前的抗体即时检测无法区分母亲和婴儿的
检测婴儿是否感染人类免疫缺陷病毒的抗体
病毒(HIV)。根据卫生组织/艾滋病规划署/儿童基金会最近的一份联合报告,
28%的艾滋病毒阳性母亲所生的婴儿在出生后第一个月内接受了艾滋病毒检测。
两个月[1]。因此,对于新的和改进的诊断存在未满足的需求,
可以应用在护理点检测艾滋病毒感染。一种高度敏感、简单
将开发在护理点检测艾滋病毒的试纸分子测试。的
使用塔拉(模板辅助快速测定)扩增靶序列
该技术由模板依赖性化学转移反应组成,
高周转率、金纳米颗粒-HRP和侧流读出。测试应该是快速的
(<30分钟),并导致出现有色条带,可通过
眼睛或使用智能手机扫描仪捕获。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HyunDae Cho其他文献
HyunDae Cho的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HyunDae Cho', 18)}}的其他基金
Point of Care HPV 16/18/45 DNA Test for Cervical Cancer
宫颈癌护理点 HPV 16/18/45 DNA 检测
- 批准号:
10896570 - 财政年份:2023
- 资助金额:
$ 28.15万 - 项目类别:
Point of Care HPV 16/18/45 DNA Test for Cervical Cancer
宫颈癌护理点 HPV 16/18/45 DNA 检测
- 批准号:
10010422 - 财政年份:2020
- 资助金额:
$ 28.15万 - 项目类别:
Rapid Point-of-Care RNA Diagnostic for Dengue Infection
登革热感染的快速护理点 RNA 诊断
- 批准号:
10436535 - 财政年份:2019
- 资助金额:
$ 28.15万 - 项目类别:
A Rapid HIV RNA Detection without Sample Preparation
无需样品制备的快速 HIV RNA 检测
- 批准号:
10017696 - 财政年份:2019
- 资助金额:
$ 28.15万 - 项目类别:
Rapid Point-of-Care RNA Diagnostic for Dengue Infection
登革热感染的快速护理点 RNA 诊断
- 批准号:
10469689 - 财政年份:2019
- 资助金额:
$ 28.15万 - 项目类别:
Point of Care Nucleic Acids Test for the Liver Flukes Opisthorchis viverrini and Clonorchis
肝吸虫、维韦里尼后睾吸虫和华支睾吸虫的护理点核酸检测
- 批准号:
10022036 - 财政年份:2019
- 资助金额:
$ 28.15万 - 项目类别:
A Rapid HIV RNA Detection without Sample Preparation
无需样品制备的快速 HIV RNA 检测
- 批准号:
10909467 - 财政年份:2019
- 资助金额:
$ 28.15万 - 项目类别:
A Rapid HIV RNA Detection without Sample Preparation
无需样品制备的快速 HIV RNA 检测
- 批准号:
10263340 - 财政年份:2019
- 资助金额:
$ 28.15万 - 项目类别:
Rapid, Point-of-Care Nucleic Acid Test for HCV
HCV 快速护理点核酸检测
- 批准号:
10017197 - 财政年份:2019
- 资助金额:
$ 28.15万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 28.15万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 28.15万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 28.15万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 28.15万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 28.15万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 28.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 28.15万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 28.15万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 28.15万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 28.15万 - 项目类别:














{{item.name}}会员




